Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first-line therapy

Hit me with your best shot

(2015) Jennifer Cohn et al.   AIDS

In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2

(2015) Robert A Smith et al.   Retrovirology

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence

(2015) Thibault Mesplède et al.   Viruses-Basel

Differential Effects of the G118R, H51Y, and E138K Resistance Substitutions in Different Subtypes of HIV Integrase

(2015) Peter K. Quashie et al.   JOURNAL OF VIROLOGY

Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study

(2014) Bisher Akil et al.   ANTIVIRAL THERAPY

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

(2014) A. Castagna et al.   JOURNAL OF INFECTIOUS DISEASES

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

(2014) Bonaventura Clotet et al.   LANCET

What if HIV were unable to develop resistance against a new therapeutic agent?

(2013) Mark A Wainberg et al.   BMC Medicine

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

(2013) Pedro Cahn et al.   LANCET

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

(2013) Francois Raffi et al.   LANCET

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

(2013) François Raffi et al.   LANCET INFECTIOUS DISEASES

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

(2013) Sharon L. Walmsley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure

(2013) Thibault Mesplède et al.   Retrovirology

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

(2012) Joseph J. Eron et al.   JOURNAL OF INFECTIOUS DISEASES